Valeant Pharmaceuticals ups its unsolicited bid for Allergan by $10 per share to $58.50 apiece and says it will add a contingent value right for Allergan's Darpin eye drug worth $25 per share.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1mFbPXi
Cap comentari:
Publica un comentari a l'entrada